These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22032264)

  • 1. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.
    Wray S; Armstrong R; Herrman C; Calkwood J; Cascione M; Watsky E; Hayward B; Mercer B; Dangond F
    Expert Opin Drug Deliv; 2011 Dec; 8(12):1543-53. PubMed ID: 22032264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
    Singer B; Wray S; Miller T; Cascione M; Gupta A; Pardo G; Watsky E; Hayward B; Mercer B; Dangond F
    Mult Scler Relat Disord; 2012 Apr; 1(2):87-94. PubMed ID: 25876936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
    Devonshire V; Arbizu T; Borre B; Lang M; Lugaresi A; Singer B; Verdun di Cantogno E; Cornelisse P
    BMC Neurol; 2010 Apr; 10():28. PubMed ID: 20433746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
    Wray S; Hayward B; Dangond F; Singer B
    Expert Opin Drug Deliv; 2018 Feb; 15(2):127-135. PubMed ID: 29206056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
    Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
    Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J;
    Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.
    Arroyo E; Grau C; Ramo-Tello C; Parra J; Sánchez-Soliño O;
    Eur Neurol; 2011; 65(2):59-67. PubMed ID: 21212677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
    Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
    Giovannoni G; Barbarash O; Casset-Semanaz F; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Mult Scler; 2009 Feb; 15(2):219-28. PubMed ID: 18755819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
    Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA
    Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
    Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
    BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
    Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
    BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
    Zecca C; Disanto G; Mühl S; Gobbi C
    BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
    Bayas A; Ouallet JC; Kallmann B; Hupperts R; Fulda U; Marhardt K;
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1239-50. PubMed ID: 26098143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
    Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
    Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.